Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine
NCT04672473
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Malignant Tumor
Interventions
BIOLOGICAL:
DC-CTL
Sponsor
Shenzhen University General Hospital